These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8801857)

  • 61. [Comparative antigenic activity of the hepatitis A inactivated vaccine among military personnel].
    Shumilov VI; Shevtsov VA; Lobastov SP; Salmina TA; Shervarli VI; Vardanian NV; Nikolaeva EI
    Voen Med Zh; 2004 Jan; 325(1):62-5. PubMed ID: 15038272
    [No Abstract]   [Full Text] [Related]  

  • 62. [Hep-A-in-Vac, a Russian cultured concentrated inactivated vaccine against hepatitis A].
    Gorbunov MA; Pavlova LI; Rozhkov SD; Kukharev AI; Novikov VIu; Karpovich LG; Kalashnikova TV; Bektimirov TA; Zelenov IA; Levina VD; Belashev BP; Ermolaeva TN; Doroshenko NV; Maĭdaniuk AT
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (1):50-4. PubMed ID: 9532686
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Studies on vaccination schedule of inactivated hepatitis A vaccine].
    Hu Y; Tan S; Jin W
    Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):618-20. PubMed ID: 11798830
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile.
    Valenzuela MT; Jacobs RJ; Arteaga O; Navarrete MS; Meyerhoff AS; Innis BL
    Vaccine; 2005 Jul; 23(32):4110-9. PubMed ID: 15964479
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Committee on Native American Child Health and Committee on Infectious Diseases. Immunizations for Native American children. American Academy of Pediatrics.
    Pediatrics; 1999 Sep; 104(3 Pt 1):564-7. PubMed ID: 10469787
    [No Abstract]   [Full Text] [Related]  

  • 66. Immunogenecity of hepatitis A vaccine in children below 2 years of age.
    Mittal SK; Rastogi A
    Indian Pediatr; 1999 Jan; 36(1):97. PubMed ID: 10709135
    [No Abstract]   [Full Text] [Related]  

  • 67. Prevention of hepatitis A by Havrix: a review.
    Van Herck K; Van Damme P
    Expert Rev Vaccines; 2005 Aug; 4(4):459-71. PubMed ID: 16117704
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Administration of hepatitis A vaccine to a military population by needle and jet injector and with hepatitis B vaccine.
    Hoke CH; Egan JE; Sjogren MH; Sanchez J; DeFraites RF; MacArthy PO; Binn LN; Rice R; Burke A; Hill J
    J Infect Dis; 1995 Mar; 171 Suppl 1():S53-60. PubMed ID: 7876650
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hepatitis vaccination among drug users.
    Quaglio G; Lugoboni F; Mezzelani P; Des Jarlais DC; Lechi A
    Vaccine; 2006 Apr; 24(15):2702-9. PubMed ID: 16436307
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Who should receive hepatitis A vaccine?
    Brewer MA; Edwards KM; Decker MD
    Pediatr Infect Dis J; 1995 Apr; 14(4):258-60. PubMed ID: 7603804
    [No Abstract]   [Full Text] [Related]  

  • 71. Prevention of hepatitis A virus infection.
    Moyer L; Warwick M; Mahoney FJ
    Am Fam Physician; 1996 Jul; 54(1):107-14. PubMed ID: 8677827
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inactivated hepatitis A vaccines.
    Lemon SM
    JAMA; 1994 May; 271(17):1363-4. PubMed ID: 8158824
    [No Abstract]   [Full Text] [Related]  

  • 73. [Characteristics of reactogenic and immunogenic properties of the children's variant of the domestic vaccine, "Gep-A-in-Vak", against hepatitis A].
    Ikoev VN; Gorbunov MA; Maĭdaniuk AG; Karpovich LG; Kalashnikova TV; Bektimirov TA; Karpova EV; Nemtsov IuV; Muntlieva MA; Kriuk NI
    Vopr Virusol; 1999; 44(3):133-6. PubMed ID: 10392439
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine.
    Dumas R; Forrat R; Lang J; Farinelli T; Loutan L
    Adv Ther; 1997; 14(4):160-7. PubMed ID: 10174195
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [The immunogenicity and impact factors of hepatitis A attenuated live vaccine and inactivated vaccine].
    Zheng H; Cui FQ
    Zhongguo Yi Miao He Mian Yi; 2009 Aug; 15(4):371-4. PubMed ID: 20077742
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Preventing hepatitis A infections in travelers to endemic areas.
    Koff RS
    Am J Trop Med Hyg; 1995 Dec; 53(6):586-90. PubMed ID: 8561258
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA.
    Wiens BL; Bohidar NR; Pigeon JG; Egan J; Hurni W; Brown L; Kuter BJ; Nalin DR
    J Med Virol; 1996 Jul; 49(3):235-41. PubMed ID: 8818971
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination.
    Totos G; Gizaris V; Papaevangelou G
    Vaccine; 1997 Aug; 15(11):1252-3. PubMed ID: 9286052
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inactivated virosome hepatitis A vaccine.
    Loutan L; Bovier P; Althaus B; Glück R
    Lancet; 1994 Feb; 343(8893):322-4. PubMed ID: 7905144
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vaccination against hepatitis A virus in French hemophilic children.
    Rothschild C; Pol S; Mattlinger B; Reijasse D; Torchet MF; Gazengel C
    Vox Sang; 1995; 69(1):80-1. PubMed ID: 7483502
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.